Search
Acetyl sulfisoxazole
go.drugbank.com/drugs/DB14033ApprovedVet approvedIt is often combined with erythromycin to treat acute otitis media caused by the bacteria, haemophilus influenzae [L2790].
Collagenase clostridium histolyticum
go.drugbank.com/drugs/DB00048ApprovedInvestigationalCollagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. … [L14912] On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women.
Detomidine
go.drugbank.com/drugs/DB11556InvestigationalVet approvedThis drug is prescribed by veterinarians and is marketed as _Dormosedan_. Currently, it is only approved by the FDA for use in horses but has been studied for use in other large animals.
Prussian blue
go.drugbank.com/drugs/DB06783ApprovedIt is insoluble in water but also tends to form a colloid thus can exist in either colloidal or water-soluble form, and an insoluble form.
Metoprolol
go.drugbank.com/drugs/DB00264ApprovedInvestigational[A175162] Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.[L5527]
Procaterol
go.drugbank.com/drugs/DB01366ApprovedWithdrawnIt is a potent bronchodilator that may be administered orally or by aerosol inhalation.
Drotrecogin alfa
go.drugbank.com/drugs/DB00055ApprovedWithdrawnDrotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. … It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond.
Zinc sulfate, unspecified form
go.drugbank.com/drugs/DB14548ApprovedZinc sulfate is a common zinc supplement in parenteral nutrition.
Mixtures: Quality Choice Eye Drops Irritation ReliefDutasteride
go.drugbank.com/drugs/DB01126ApprovedInvestigationalIt is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. … Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to